Claris Biotherapeutics, Inc.

This early study tests an experimental eye drop (CSB-001) in 20 people with recent corneal scars (formed 7-30 days ago). Participants use the drops 3-4 times daily for up to 14 days. The main goals are to check safety and see if the drops reduce scar size and improve vision.

This early-stage study is testing whether a new eye drop called CSB-001 can help people with limbal stem cell deficiency, a condition that damages the clear front part of the eye (cornea) and can lead to vision loss. About 65 participants will use the eye drops in one or both eye…